Back to search


KVAL: Gene therapy for osteoarthritis and other inflammatory conditions

Alternative title: Genterapi mot artrose og andre inflammatoriske sykdommer

Awarded: NOK 0.50 mill.

Project Number:


Project Period:

2021 - 2022

Funding received from:



Gene therapy for osteoarthritis and other inflammatory conditions Osteoarthritis (OA) is the most common joint disease leading to pain, physical incapacities, reduced quality of life for hundred millions of people worldwide and tremendous economical burden for the society as a whole. The prevalence of OA is on the rise and there is no disease modifying treatment. The only treatments today are pain relieving options like painkillers and physiotherapy. The final outcome is often total joint replacement. Gene therapy might become a game changer for these grim numbers and sad outcomes. We aim to use specific microRNAs as therapeutic agents for OA. microRNAs (miRNAs) are small RNA molecules that can turn certain genes on and off, which makes them powerful therapeutic agents. Osteoarthritis is a complex disease where several factors and drivers are involved. This project investigated inflammation as one of the drivers behind OA. The project also aims to tackle the disease using specific miRNAs that showed strong inhibitory effects against inflammation and other important immune responses. In this way one might be able to protect the cartilage and the whole joint from the destructive inflammatory response and prevent joint degradation. This project will help bring the therapeutic agents and gene therapy closer to the clinic. The miRNAs of interest have shown impressive anti-inflammatory effects which makes them relevant therapeutic agents for other immune conditions and arthritic diseases as well.


Funding scheme: